abrdn Life Sciences Investors (NYSE: HQL)


The Funds investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies.

Daily Data As of {{asOfDate}}

{{item.label}} {{item.value}} {{item.unit}}

The NAV information is provided by the Fund's accounting agent. The price is as reported by the exchange on which the Fund trades. This information is unaudited and neither abrdn Inc., its wholly owned subsidiaries, the Funds, nor any other person guarantees their accuracy.

Key Facts

Ticker symbol HQL (NYSE)

Gross Expense Ratio* 1.35%

Net Expense Ratio* 1.35%


* as of 09/30/2023
** as of 04/30/2024
*** as of 04/30/2024

Net assets** $417,477,618.29

Shares outstanding** 27,350,516

NAV Distribution Rate***6.7%

Fiscal year endedSeptember 30

Market Distribution Rate*** 7.5%

The annual distribution rate an investor would receive if the most recent fund distribution and current fund price stayed the same going forward. It is calculated by annualizing the most recent distribution and dividing by the fund’s market price from the as-of-date. The distribution rate may include a return of capital. Please refer to the “Section 19 Notices” section of the fund’s website for the most recent Section 19 notice that provides estimated amounts and sources of the fund’s distributions, which should not be relied upon for tax reporting purposes.

Podcasts